Umeclidinium bromide: Difference between revisions

Umeclidinium bromide
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Latest revision as of 00:44, 18 February 2025

A medication used in the management of chronic obstructive pulmonary disease

Umeclidinium bromide is a medication used in the management of chronic obstructive pulmonary disease (COPD). It is a long-acting muscarinic antagonist (LAMA) that helps to open the airways and make breathing easier.

Medical uses[edit]

Umeclidinium bromide is primarily used as a maintenance treatment for COPD. It is not indicated for the relief of acute bronchospasm or for the treatment of asthma. The medication is administered via inhalation, typically once daily, using a specific inhaler device.

Mechanism of action[edit]

Umeclidinium bromide works by blocking the action of acetylcholine on muscarinic receptors in the airways. This action leads to the relaxation of bronchial smooth muscle, resulting in bronchodilation and improved airflow in patients with COPD.

Side effects[edit]

Common side effects of umeclidinium bromide include dry mouth, cough, and upper respiratory tract infections. Less common but more serious side effects can include urinary retention and paradoxical bronchospasm.

Pharmacokinetics[edit]

After inhalation, umeclidinium bromide is absorbed into the bloodstream, where it reaches peak plasma concentrations within a few hours. It is metabolized primarily by the liver and excreted in the urine and feces.

History[edit]

Umeclidinium bromide was developed by GlaxoSmithKline and was approved for medical use in the United States in 2013. It is often combined with other medications, such as vilanterol, to enhance its therapeutic effects.

Related pages[edit]

References[edit]

Chemical structure of Umeclidinium bromide
3D model of Umeclidinium bromide

@@ Line 1: / Line 1: @@
-'''Umeclidinium bromide''' is a long-acting muscarinic antagonist (LAMA) used in the management of [[chronic obstructive pulmonary disease]] (COPD). It is marketed under the brand name '''Incruse Ellipta''' by [[GlaxoSmithKline]].
+{{Short description|A medication used in the management of chronic obstructive pulmonary disease}}
+{{Drugbox
+| verifiedfields = changed
+| verifiedrevid = 477002123
+| IUPAC_name = (1R,2R,4S,5S)-4-[(hydroxydi-2-thienylacetyl)oxy]-1-azoniabicyclo[2.2.2]octane bromide
+| image = Umeclidinium_bromide.svg
+| image2 = Umeclidinium_bromide_3D.png
+}}
-==Pharmacology==
+'''Umeclidinium bromide''' is a [[medication]] used in the management of [[chronic obstructive pulmonary disease]] (COPD). It is a long-acting muscarinic antagonist (LAMA) that helps to open the airways and make breathing easier.
-Umeclidinium bromide is a [[muscarinic receptor antagonist]], which means it works by blocking the action of [[acetylcholine]], a neurotransmitter that can cause bronchoconstriction. By blocking the action of acetylcholine, umeclidinium bromide helps to relax and open the airways, making it easier for people with COPD to breathe.
-==Clinical Use==
+==Medical uses==
-Umeclidinium bromide is used as a maintenance treatment for COPD. It is not used to relieve sudden breathing problems and won't replace a rescue inhaler. The medication is usually inhaled once a day using a special inhaler device.
+Umeclidinium bromide is primarily used as a maintenance treatment for COPD. It is not indicated for the relief of acute bronchospasm or for the treatment of asthma. The medication is administered via inhalation, typically once daily, using a specific inhaler device.
-==Side Effects==
+==Mechanism of action==
-Common side effects of umeclidinium bromide include upper respiratory tract infection, stuffy or runny nose, cough, mouth and throat pain, joint pain, change in taste, and urinary tract infection. Serious side effects may include allergic reactions, new or worsening eye problems, and new or worsening urinary problems.
+Umeclidinium bromide works by blocking the action of acetylcholine on muscarinic receptors in the airways. This action leads to the relaxation of bronchial smooth muscle, resulting in bronchodilation and improved airflow in patients with COPD.
-==Interactions==
+==Side effects==
-Umeclidinium bromide may interact with other drugs that also block acetylcholine, such as other anticholinergics. It may also interact with certain drugs used for Parkinson's disease, depression, or other psychiatric or emotional conditions.
+Common side effects of umeclidinium bromide include dry mouth, cough, and upper respiratory tract infections. Less common but more serious side effects can include urinary retention and paradoxical bronchospasm.
-==See Also==
+==Pharmacokinetics==
+After inhalation, umeclidinium bromide is absorbed into the bloodstream, where it reaches peak plasma concentrations within a few hours. It is metabolized primarily by the liver and excreted in the urine and feces.
+==History==
+Umeclidinium bromide was developed by [[GlaxoSmithKline]] and was approved for medical use in the United States in 2013. It is often combined with other medications, such as [[vilanterol]], to enhance its therapeutic effects.
+==Related pages==
 * [[Chronic obstructive pulmonary disease]]
 * [[Muscarinic antagonist]]
-* [[Acetylcholine]]
 * [[GlaxoSmithKline]]
-[[Category:Drugs]]
+==References==
-[[Category:Pharmacology]]
+{{Reflist}}
-[[Category:Respiratory system]]
-{{Pharma-stub}}
+[[Category:Bronchodilators]]
+[[Category:Quaternary ammonium compounds]]
+[[Category:Muscarinic antagonists]]
+<gallery>
+File:Umeclidinium_bromide.svg|Chemical structure of Umeclidinium bromide
+File:Umeclidinium_bromide_3D.png|3D model of Umeclidinium bromide
+</gallery>